Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech
An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech

Diabetes

  • Article

    Effects of Semaglutide on CKD in Patients with Type 2 Diabetes: the FLOW Trial

    April 1, 2025

    Clinical question: Does treatment with semaglutide in patients with type 2 diabetes and chronic kidney disease (CKD) prevent the progression of CKD or death from kidney and cardiovascular...

  • Article

    There is a Decreased Risk of Hospitalization from Heart Failure in Type II Diabetics Initiated on a SGLT2 Inhibitor When Compared to a GLP-1 Receptor Agonist

    September 1, 2022

    Dr. Huang Clinical question: Determine the cardiovascular risk outcome in type II diabetic patients initiated on an sodium-glucose cotransporter-2 (SGLT2)  inhibitor versus a glucagon-like...

  • Article

    Many hospitalized patients with type 2 diabetes and mild hyperglycemia on admission can be managed with sliding scale insulin alone

    January 7, 2022

    Dr. Knees Clinical question: In patients with mild hyperglycemia on admission, can sliding scale insulin (SSI) alone be used for blood glucose (BG) control? Background: Prior randomized...

  • 1
    News

    Care via video teleconferencing can be as effective as in-person for some conditions

    December 6, 2021

    Video teleconferencing works best for monitoring patients with chronic conditions, according to the author of a new paper.

  • 1
    News

    SGLT2 inhibitor use tied to fewer atrial arrhythmias

    December 2, 2021

    A prospective study of nearly 14,000 patients who received an implantable cardiac device suggests that SGLT2-inhibitor treatment cuts atrial arrhythmias.

  • 1
    News

    Empagliflozin a winner in challenging arena of stabilized acute HF

    November 19, 2021

    Early in-hospital initiation of SGLT2 inhibitors “should be considered the new standard of care” in most patients with heart failure regardless of their ejection fraction, says an expert observer.

  • 1
    News

    EMPEROR-Preserved findings confirmed in ‘true’ HFpEF patients

    November 17, 2021

    A landmark trial proved empagliflozin’s efficacy in HFpEF, but many patients had “moderately reduced” EFs. The findings hold up even without them.

  • News

    Some diabetes drugs may lower risk of severe COVID-19 outcomes

    October 19, 2021

    Glucose-regulating medications may improve outcomes in COVID-19 patients with type 2 diabetes, a multinational retrospective cohort study suggests.

  • News

    Age, C-reactive protein predict COVID-19 death in diabetes

    September 29, 2021

    “This means we can easily identify patients early on in their hospital stay who will likely require more aggressive interventions to try and improve survival.”

  • 1
    News

    Heart failure hospitalization risk lower with SGLT2 inhibitors than GLP-1 RAs

    September 27, 2021

    SGLT2 inhibitor versus GLP-1 RA use was associated with a significantly lower rate of hospitalization for heart failure in people with diabetes.

1 2 3 … 14Next
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
fa-facebookfa-linkedinfa-instagramfa-youtube-playfa-commentfa-envelopefa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.
    ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences